Lilly, Boehringer celebrate Synjardy's FDA nod; Bayer moves heart failure med into Phase III;

> Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's new diabetes combo med Synjardy--which combines the active ingredient in the SGLT2 drug Jardiance with metformin--won U.S. approval, becoming the third empagliflozin product blessed by the FDA. Release

> Bayer is advancing its new heart failure drug into Phase III testing after the drug, finerenone, posted a "striking" reduction in deaths in a mid-stage trial. Report

> Allergan ($AGN) wrapped up its $560-million-plus deal for Naurex and its two antidepressants, which recently posted promising mid-stage data. Release

> France's Ipsen said its muscle injection Dysport, a competitor to Allergan's Botox, proved effective and safe at treating upper limb spasticity in adults with neurological disorders. Report

> Endo International ($ENDP) said its Xiaflex drug for Dupuytren's Contracture now has official pricing in Japan and is set for a mid-September launch there. Release

And Finally... Frequent use of antibiotics might boost the risk of Type 2 diabetes, a study found. Report

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.